Describing biotech billionaire Patrick Soon-Shiong as a big thinker is an understatement given the goals that he and his web of businesses have for improving the way cancer patients are treated, and now he's enlisting the help of other biopharma companies to test immunotherapy hypotheses.
Soon-Shiong Envisions Better, Ultimately Cheaper Cancer Care
Describing biotech billionaire Patrick Soon-Shiong as a big thinker is an understatement given the goals that he and his web of businesses have for improving the way cancer patients are treated, and now he's enlisting the help of other biopharma companies to test immunotherapy hypotheses.
More from Anticancer
More from Therapy Areas
• By
The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.
• By
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
• By
Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.